Alfasigma expands its footprints in the U.S. through the acquisition of Pamlab

The company is active in the manufacturing and distribution of medical food products, a high-growth market segment.


Alfasigma, among the top five players in the Italian pharmaceutical industry, announces the acquisition of Pamlab, a U.S. based company with a leading position in the manufacturing and distribution of medical foods, from Nestlé Health Science.

Pamlab is a specialty pharmaceutical company focused on high-growth market segments of medical foods for brain and metabolic health, mainly serving patients with depression, diabetic neuropathy and mild cognitive impairment.

Pamlab has a proven track record in the medical foods market in the US.

The company has a significant market share in the clinical dietary management of depression, diabetic peripheral neuropathy and cognitive impairment thanks to its brands, in particular Deplin®, Metanx® and CerefolinNAC®.

Pamlab, with the headquarters in Covington and a manufacturing site in Shreveport (Louisiana), has approximately 300 employees of which 180 are field sales reps.

For many years now, Alfasigma’s rifaximin product has been marketed in the U.S. under the tradename Xifaxan® by license to Salix / Valeant. Alfasigma further strengthened its presence in the world’s largest market by creating Sigma-Tau Healthscience USA, Inc., which markets VSL#3, a potent probiotic medical food bought, in June 2016 and now by acquiring Pamlab.

Thanks to this transactions, in 2017 Alfasigma expects to reach a total turnover in the U.S. market of approx. USD 200 million.

“Pamlab is a perfect opportunity to make an additional step towards the extension of Alfasigma geographic footprint in the US, a pivotal market in the group internationalization plan. We are pleased to have completed this transaction, as Pamlab will represent an important growth platform thanks to its commercial network, its portfolio of unique and high-quality products and its competitive position in an attractive market segment with significant opportunities for growth”, said Mr. Stefano Golinelli, Chairman of Alfasigma.

Four Partners Advisory S.p.A. acted as Financial Advisor to Alfasigma in the acquisition.

Press release & Attachments


You’re entering Alfasigma global website

I agree